IDERA - Key Persons

Job Titles:

• Chief Business Officer
• General Counsel
• Member of the MANAGEMENT Team
• Senior Vice President
• General Counsel and Secretary of the Board of Directors

Bryant D. Lim joined Idera in September of 2018 as Senior Vice President, Chief Business Officer and General Counsel. Prior to joining Idera, Mr. Lim served as Vice President, Assistant General Counsel of Incyte Corporation. Prior to Incyte, Mr. Lim held roles of increasing responsibility at ViroPharma Incorporated, Merck & Co., Inc. and Morgan, Lewis & Bockius, LLP. Mr. Lim began his legal career as a law clerk for a federal judge. Mr. Lim currently serves on the board of directors for Life Sciences Pennsylvania, the state biotechnology industry association. Mr. Lim holds a J.D. from Villanova University School of Law and a Bachelor of Arts from University of Rochester.

Job Titles:

• DIRECTOR
• Member of the Audit Committee
• Audit Committee
• Member of Idera 's Board of Directors

Carol Schafer was appointed a member of Idera's Board of Directors in December 2018. Ms. Schafer is a seasoned financial professional with more than 25 years of experience in investment banking and equity capital markets, as well as corporate finance and business development in the biopharmaceutical sector, with substantial experience financing and facilitating investor access for public and private healthcare companies. Ms. Schafer most recently served as Vice Chair, Equity Capital Markets at Wells Fargo Securities LLC. Prior to Wells Fargo, Ms. Schafer served as Vice President of Finance and Business Development at Lexicon Pharmaceuticals. Earlier in her career, Ms. Schafer served as an Equity Capital Markets Sector Head in her role as Managing Director at J.P. Morgan Chase & Co. Ms. Schafer has served on the board of directors of Repare Therapeutics since 2019, of Insmed since 2020, and of Kura Oncology since 2021. Ms. Schafer also has served as a board member of OneGoal NY, a non-profit entity, since 2019. Ms. Schafer previously served on the board of directors of Five Prime Therapeutics from 2019 until 2021 when it was acquired by Amgen Inc. Ms. Schafer holds a B.A. from Boston College and an M.B.A. from New York University.

Job Titles:

• Member of Idera 's Board of Directors

Cristina Csimma was appointed a member of Idera's Board of Directors in April 2019. Dr. Csimma has also served on the boards of directors of Syncona Partners since 2022 and Palisade Bio since 2021, and as the chair of the board of directors of Caraway Therapeutics since 2019, including as executive chair in 2019. Dr. Csimma is also on the advisory boards of the Muscular Dystrophy Association Venture Philanthropy Scientific Advisory Committee, the Harvard and Brigham and Women's Hospital MRCT Center External Advisory Board, the TREAT-NMD Advisory Committee for Therapeutics (TACT), and the Executive Oversight Board to the National Institutes of Health (NIH) NeuroNext Network. Dr. Csimma previously served as chair and executive chair of the board of directors of Forendo Pharma, and she was a director on the board of Seneca Biopharma until its merger with Leading BioSciences to form Palisade Bio. She has also served as a director on the boards of Juniper Pharmaceuticals and Vtesse, was the executive chair and a senior advisor of Exonics Therapeutics, and was President, founding CEO, and board director of Cydan. Dr. Csimma also served on the NIH Blueprint Neurotherapeutics Network External Oversight Committee, was Vice President of Drug Development at Virdante Pharmaceuticals Inc., Principal at Clarus Ventures, and held roles of increasing responsibility in Clinical Development and Translational Research at Wyeth, Genetics Institute, and Dana Farber Cancer Institute. Dr. Csimma holds both a Doctor of Pharmacy and a Bachelor of Science in Pharmacy from the Massachusetts College of Pharmacy and Allied Health Sciences, as well as a Master of Health Professions from Northeastern University.

Job Titles:

• Chief Operating Officer
• Member of the MANAGEMENT Team
• Senior Vice President

Daniel Soland joined Idera as Senior Vice President and Chief Operating Officer in January 2021. Mr. Soland previously served as the Chief Executive Officer of uniQure N.V. and, prior to that, Senior Vice President & COO of ViroPharma Inc. While at ViroPharma, Mr. Soland managed the commercial, manufacturing, and quality organizations, helped build the company's commercial infrastructure in the U.S., Europe, and Canada, and led the launch of Cinryze® (C1 esterase inhibitor [human]), one of the most successful ultra-orphan drug launches in the U.S. Mr. Soland also served as President, Chiron Vaccines, of Chiron Corporation from 2005 to 2006 and led the growth of the vaccine business to over $1 billion in sales. From 2002 through 2005, Mr. Soland served as President and Chief Executive Officer of Epigenesis Pharmaceuticals. Earlier in his career, Mr. Soland worked for GlaxoSmithKline in increasing roles of responsibility, including as Vice President and Director, Worldwide Marketing Operations, GSK Biologicals. He currently serves on the Board of Directors of Acadia Pharmaceuticals, Inc., DBV Technologies SA, and KalVista Pharmaceuticals, Inc. Mr. Soland earned his B.S. in Pharmacy from the University of Iowa.

Job Titles:

• Member of the MANAGEMENT Team
• Senior Vice President, Product Leadership

Elizabeth Eberhardt joined Idera in January 2020 and is Senior Vice President of Product Leadership. Prior to joining Idera, she held senior leadership positions in program management at Tmunity Therapeutics, Trevena, Inc. and, until its acquisition by Shire, ViroPharma Incorporated. Throughout her career, she has advanced multiple drug candidates through all phases of development and commercialization. She also has extensive experience in leading global product teams, specialty project teams, and strategic alliances. Ms. Eberhardt continues to have a strong commitment to the mentorship of aspiring leaders in her organizations. She graduated magna cum laude from East Carolina University with a Bachelor of Science in business administration.

Job Titles:

• DIRECTOR
• Member of the Audit Committee
• Member of Idera 's Board of Directors and Chair of the Board
• Nominating & Corporate Governance Committee

James Geraghty was appointed a member of Idera's Board of Directors and Chair of the Board in July 2013, a position he held until April 2021. Mr. Geraghty is an industry leader with over 35 years of strategic and leadership experience, including more than 25 years as a senior member of executive teams at biotechnology companies developing and commercializing innovative therapies. Mr. Geraghty previously was an Entrepreneur in Residence at Third Rock Ventures, a leading biotech venture fund, from 2013 to 2016, and served as a Senior Vice President of Sanofi S.A., a global healthcare company from 2011 to 2012. Prior to that, he served in various senior management roles at Genzyme Corporation, or Genzyme, a biotechnology company, including as Senior Vice President, International Development and President of Genzyme Europe. Mr. Geraghty currently serves as chairman of the boards of Orchard Therapeutics and Pieris Pharmaceuticals and as a member of the boards of Voyager Therapeutics and Fulcrum Therapeutics. He also previously served as a director of bluebird bio and GTC Biotherapeutics. Mr. Geraghty holds a J.D. from the Yale Law School, a Master of Science from the University of Pennsylvania, and a Bachelor of Arts degree from Georgetown University.

Job Titles:

• Member of the MANAGEMENT Team
• Senior Vice President, Human Resources
• Senior Vice President, Investor Relations & Corporate Communications

Jill Conwell joined Idera as Senior Vice President, Human Resources in February 2015. In February 2020, Ms. Conwell additionally assumed responsibility for Investor Relations & Corporate Communications. Prior to joining Idera, she served as Senior Human Resources Director at Shire Pharmaceuticals, where she partnered with business leaders in many segments of that company in aligning their organization strategy, structure, and plans with the overall business strategy. Prior to joining Shire, Ms. Conwell held roles of increasing responsibility at Accenture in that company's Health & Life Sciences Consulting practices and with MacDermid, Inc. Ms. Conwell holds a Bachelor of Science degree in chemical engineering from the University of Virginia and an MBA from the Wharton School at the University of Pennsylvania.

Job Titles:

• Chief Financial Officer
• Member of the MANAGEMENT Team
• Senior Vice President

John Kirby joined the company in 2015 and was appointed Chief Financial Officer in July 2019. Before joining Idera, Mr. Kirby served as Assistant Controller at Endo Pharmaceuticals. Prior to joining Endo, Mr. Kirby served as Vice President, Chief Accounting Officer and Corporate Controller at ViroPharma Incorporated. Mr. Kirby began his career at KPMG, LLP and served as a Regional Audit Director at AstraZeneca Pharmaceuticals prior to joining ViroPharma. Mr. Kirby received his Bachelor of Science from Villanova University and is a licensed certified public accountant.

Job Titles:

• DIRECTOR
• Member of the Audit Committee
• Audit Committee
• Member of Idera 's Board of Directors

Mark Goldberg was appointed a member of Idera's Board of Directors in January 2014. Dr. Goldberg has also served as a member of the board of directors of ImmunoGen since 2011, a member of the board of directors of GlycoMimetics since 2014, a member of the board of directors of Blueprint Medicines Corporation since 2015, and a member of the board of directors of Avacta Group since 2021. In addition, he is a member of the board of directors of the American Cancer Society, a non-profit organization. Dr. Goldberg previously served on the boards of directors of Audentes Therapeutics from 2017 until 2020 and aTyr Pharma from 2015 until 2017. He also served in several capacities with Synageva BioPharma from 2011 until 2015, including as an advisor and medical and regulatory strategist, Executive Vice President for Medical and Regulatory Strategy, and Senior Vice President of Medical and Regulatory Affairs. Dr. Goldberg also previously served in a variety of senior management positions at Genzyme Corporation, including as Senior Vice President for Clinical Development and Therapeutic Group Head for Oncology and Personalized Genetic Health. He was also the Chairman of Genzyme's Early Product Review Board. While at Genzyme, he played a central role in the development and approval of some of the benchmark therapies for rare diseases, including Fabrazyme®, Aldurazyme®, Myozyme®, and Lumizyme®. Prior to working at Genzyme, he was a full-time staff physician at Brigham and Women's Hospital and Dana Farber Cancer Institute. He was also an Associate Professor of Medicine at Harvard Medical School from 1996 until 2021 and is currently a lecturer and part-time faculty at Harvard Medical School. Dr. Goldberg is a board-certified medical oncologist and hematologist and has more than 50 published papers. He holds an A.B. from Harvard College and an M.D. from Harvard Medical School.

Job Titles:

• DIRECTOR
• Member of the Audit Committee
• Compensation Committee
• Member of Idera 's Board of Directors
• Member of the Boards of Directors of Aclaris Therapeutics

Maxine Gowen was appointed a member of Idera's Board of Directors in January 2016. Dr. Gowen also has served as a member of the boards of directors of Aclaris Therapeutics since 2019, Merus NV since 2021, and Passage Bio, including as the chair of the board, since 2021. Dr. Gowen served as the CEO and a board director of TamuroBio Inc., a privately held drug development company, from 2019 to 2021; she remains a member of its board of directors. She was also the founding President and CEO of Trevena from 2007 until her retirement in 2018; she remained a member of its board of directors until 2021. Prior to joining Trevena, Dr. Gowen was Senior Vice President for the Center of Excellence for External Drug Discovery at GlaxoSmithKline plc, or GSK, where she held a variety of leadership positions during her 15-year tenure. Before GSK, Dr. Gowen was Senior Lecturer and Head, Bone Cell Biology Group, Department of Bone and Joint Medicine, of the University of Bath, U.K. She also previously held a board seat in the state biotechnology industry association, Life Sciences Pennsylvania, from 2015 until 2021, and in the national biotechnology industry association, BIO, from 2008 until 2018. In addition, Dr. Gowen previously served as a director of Human Genome Sciences, Inc., from 2008 until 2012, Akebia Therapeutics, Inc. from 2014 until 2021, and Panorama Medicine from 2020 until 2021. Dr. Gowen holds a Ph.D. from the University of Sheffield, U.K., an M.B.A. with academic honors from The Wharton School of the University of Pennsylvania, and a B.Sc. with Honors in Biochemistry from the University of Bristol, U.K.

Job Titles:

• Chairman of the Board
• DIRECTOR
• Member of the Audit Committee
• Audit Committee
• Member of Idera 's Board of Directors

Michael Dougherty was appointed a member of Idera's Board of Directors in April 2019 and was elected Chair of the Board in April 2021. Mr. Dougherty also serves on the boards of directors of Trevena, Inc. and Marinus Pharmaceuticals, Inc., both publicly traded life sciences companies. Mr. Dougherty previously served as the executive chairman of Celator Pharmaceuticals, Inc. from August 2015 until its acquisition by Jazz Pharmaceuticals in July 2016, and as a director of Celator from July 2013 to July 2016. Mr. Dougherty also previously served in a variety of senior leadership positions in the biopharmaceutical industry, including Chief Executive Officer of Kalidex Pharmaceuticals, Chief Executive Officer of Adolor Corporation, Chief Operating Officer of Genomics Collaborative, Chief Executive Officer of Genaera Corporation, and Chief Financial Officer at Centocor, Inc. Mr. Dougherty also served on the boards of directors of Foundation Medicine, Aviragen Therapeutics, and Cempra, and of ViroPharma Incorporated from 2004 until its acquisition by Shire in 2014. Mr. Dougherty holds a Bachelor of Science in Accounting from Villanova University.

Job Titles:

• Chief Executive Officer
• DIRECTOR
• Member of the MANAGEMENT Team
• President
• Chairman of the Board for Life Science Cares Philadelphia

Vincent Milano has been Idera's President and CEO, and a member of our board of directors, since 2014. Prior to joining Idera, Mr. Milano served as Chairman, President, and CEO of ViroPharma Incorporated, a pharmaceutical company that was acquired by Shire in 2014. Prior to being appointed CEO of ViroPharma, he served in increasing roles of responsibility in finance, administration, and operations, including as Chief Financial Officer and Chief Operating Officer. Prior to joining ViroPharma, Mr. Milano served in increasingly senior roles, most recently senior manager, at KPMG LLP, an independent registered public accounting firm, from 1985 to 1996. Mr. Milano has also served on the boards of directors of Aclaris Therapeutics, Inc. since 2020, BioCryst Pharmaceuticals, Inc., since 2021, and VenatoRx Pharmaceuticals, Inc., since 2013. Mr. Milano previously served as a member of the boards of directors of Spark Therapeutics and Vanda Pharmaceuticals from 2014 to 2019 and 2010 to 2019, respectively. Mr. Milano is also the Chairman of the Board for Life Science Cares Philadelphia, a collective effort of the life sciences industry to reduce the impact of poverty on its neighbors, and is a former member and chair of Life Sciences Pennsylvania, the state biotechnology industry association. He holds a Bachelor of Science degree in Accounting from Rider College.